# US 2008/0269178 A1 · Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269178 A1
- Document ID: US20080269178A1
- Status: Published application
- Kind: A1
- Application number: 11/667,872
- Filed: 2005-11-16
- Published: 2008-10-30
- Earliest claimed: 2004-11-16
- Assignees: Norton Healthcare Limited
- Inventors: John Miller; Paul Ronald; Adrian Ashley; Paul Lamb; Donald MacDonald; Martin Oliver; Matthew Pollard
- Web page: https://patentgrep.com/patent/US20080269178A1

## CPC

- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.

## Claims

### Claim 1

A method for preparing a sterile suspension of a glucocorticosteroid comprising the following steps:
(i) heating a glucocorticosteroid suspension comprising a glucocorticosteroid, water and a surfactant in a mixing vessel to sterilize the glucocorticosteroid suspension,
(ii) re-circulating the glucocorticosteroid suspension via a homogenizer before, during and/or after step (i), and subsequently
(iii) mixing the glucocorticosteroid suspension with sterile water or a sterile excipient liquid comprising water and one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

A method as claimed in claim 1, further comprising, prior to step (iii), the step of preparing the sterile water or sterile excipient liquid by passing water or an excipient liquid through a sterilizing grade filter.

### Claim 3 (depends on 1)

A method as claimed in claim 1, wherein the sterile excipient liquid is used and the one or more pharmaceutically acceptable excipients comprises a surfactant.

### Claim 4 (depends on 1)

A method as claimed in claim 1, wherein the sterile excipient liquid is used and the one or more pharmaceutically acceptable excipients comprises at least one of a buffer, a salt, a wetting agent, a stabilizing agent and an isotonic agent.

### Claim 5 (depends on 1)

A method as claimed in claim 1, wherein the re-circulating in step (ii) occurs during the heating in step (i).

### Claim 6 (depends on 1)

A method as claimed in claim 1, wherein the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from about 15 to about 300 mg/ml.

### Claim 7 (depends on 1)

A method as claimed in claim 1, wherein at least 50% of the glucocorticosteroid in the glucocorticosteroid suspension is in the form of a suspension during heating.

### Claim 8

A method as claim in 7, wherein at least 60% of the glucocorticosteroid in the glucocorticosteroid suspension is in the form of a suspension during heating.

### Claim 9 (depends on 1)

A method as claimed in claim 1, wherein the glucocorticosteroid is selected from the group consisting of at least one of beclomethasone, budesonide, ciclesonide, cortivazol, deflazacort, flumethasone, flunisolide, fluocinolone, fluticasone, mometasone, refleponide, tipredane and triamcinolone.

### Claim 10 (depends on 8)

A method as claimed in claim 8, wherein the glucocorticosteroid is beclomethasone or budesonide.

### Claim 11 (depends on 3)

A method as claimed in claim 3, wherein the concentration of the surfactant in the glucocorticosteroid suspension is from about 0.2 to about 300 mg/ml.

### Claim 12 (depends on 1)

A method as claimed in claim 1, wherein heating is carried out at a temperature of from about 101° C. to about 145° C.

### Claim 13 (depends on 12)

A method as claimed in claim 12, wherein heating is carried out at a temperature of from about 122° C. to about 138° C.

### Claim 14 (depends on 1)

A method as claimed in claim 1, wherein heating is carried out for about 2 to about 180 mins.

### Claim 15 (depends on 14)

A method as claimed in claim 14, wherein heating is carried out for at least about 30 mins.

### Claim 16 (depends on 1)

A method as claimed in claim 1, wherein the homogenizer is an in-line homogenizer or a high-pressure homogenizer.

### Claim 17 (depends on 1)

A method as claimed in claim 1, wherein, in step (iii), the sterile excipient liquid is used and the glucocorticosteroid suspension is diluted with the sterile excipient liquid to a pharmaceutically suitable concentration.

### Claim 18

A method as claimed in any preceding claim, 1 further comprising, subsequent to step (iii), packaging the sterile suspension of a glucocorticosteroid.

### Claim 19 (depends on 18)

A method as claimed in claim 18, wherein the sterile suspension of a glucocorticosteroid is packaged by a blow-fill-seal (BFS) machine.

### Claim 20 (depends on 1)

A composition comprising the sterile suspension of a glucocorticosteroid produced by the method of claim 1.

### Claim 21 (depends on 20)

A, composition as claimed in claim 20, wherein the particle size of the glucocorticosteroid is such that the Dv100 is less 20 μm, the Dv90 is less than 10 μm and the Dv50 is less than μm.
